The collaboration will provide a standardized and scalable solution to enable access to IF multiplex immunohistochemistry (IHC) assays. The joint offering will comprehensively address clinical research and translational medicine market needs by combining Ultivue’s UltiMapper™ I/O kits and services with Definiens’ first in class digital image analysis, powered by Tissue Phenomics®, supported by leading machine learning technologies. 

“We see great opportunities in expanding the existing IO-Panel solutions to IF. The collaboration with Ultivue will enable us to provide IO profiles from a single tissue section – and we can use additional serial sections to investigate other relevant biomarkers,” said Thomas Heydler, CEO, Definiens. “Analysis of spatial relationships at cellular resolution with IF multiplexing will also add biological depth and context. Ultivue’s ability to provide kits paired with Definiens’ web-based analytics infrastructure will put the power of standardized IO profiling at the fingertips of researchers across the globe.”

The joint offering...

Ultivue and Definiens scientific teams will be present at their respective company booths #2048 and #2350 at the annual meeting of the American Association of Cancer Research (AACR), from March 29 through April 3, 2019 in Atlanta, Georgia.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?